On November 6, 2022 ImmunAdd, a privately held pharmaceutical company developing a fully synthetic, rationally designed, saponin-based small molecule vaccine adjuvant, reported the company attended the Vaccines Summit 2022 in Washington DC on October 11-13 (Press release, ImmunAdd, NOV 6, 2022, View Source [SID1234654655]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Founder of ImmunAdd, Pi-Hui Liang, said "My team and I were delighted to attend the Vaccines Summit, an internationally renowned academic conference, where we presented a poster describing our state-of-the art vaccine adjuvant IA-05 and our business development team met with companies from all over the world."

The IA-05 vaccine adjuvant
IA-05 is a fully synthetic, rationally designed, saponin-based small molecule vaccine adjuvant which that has demonstrated improved tolerability and elicited improved enhanced immune responses compared with QS-21 in COVID, influenza, and anti-cancer vaccines. IA-05 can therefore enable the development of safer, more effective, and more durable vaccines and address the crisis faced by the South American soap bark tree (Quillaja Saponaria), which is being unsustainably harvested for QS-21 production. IA-05 is being tested in vaccines by several biopharmaceutical companies from different countries.